SCHEDULE: Avalo Therapeutics Stake Exceeds 5%

Avoro Capital Advisors LLC and Behzad Aghazadeh report beneficial ownership of over 5.75% of Avalo Therapeutics' common stock.

Summary

• Avoro Capital Advisors LLC, an investment advisor, and Behzad Aghazadeh, its portfolio manager, have collectively acquired a beneficial ownership stake of 1,410,000 shares of Avalo Therapeutics, Inc. common stock.
• This represents 5.75% of the company's outstanding common stock, based on 24,502,449 shares outstanding as of March 26, 2026.
• The filing is made under Schedule 13G, indicating the shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports an existing ownership stake and does not contain new operational or financial performance data.

Positives

• Significant investment by Avoro Capital Advisors LLC and Behzad Aghazadeh, indicating confidence in Avalo Therapeutics' potential.
• The reporting persons hold sole voting and dispositive power over the 1,410,000 shares, allowing for decisive action.
• The filing confirms the shares were acquired in the ordinary course of business, suggesting a standard investment strategy rather than a hostile takeover attempt.

Negatives

• The filing does not provide specific details on the acquisition cost or the exact timing of the share purchases.
• The filing is a Schedule 13G, which is typically filed by passive investors, suggesting this is not an activist stake aimed at immediate control changes.

Risks

• The filing does not explicitly mention any risks associated with the investment or the company's operations.
• Potential for increased scrutiny from other investors or regulators due to the significant ownership stake.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from the company. The reporting persons' future actions regarding their stake are not detailed, beyond the certification that the shares are held in the ordinary course of business.

Management Comments

• "The filing of this statement should not be construed as an admission that any Reporting Person is, for purposes of Section 13 of the Act, the beneficial owner of the securities reported herein."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in biotechnology and pharmaceutical companies. This filing indicates a notable investment by Avoro Capital Advisors LLC in Avalo Therapeutics, a company operating in the dynamic biotech sector, which often sees substantial institutional interest.

Stakeholder Impact

• Shareholders: The increased institutional ownership may be viewed positively, potentially indicating confidence in the company's future prospects. However, as a passive stake, it does not immediately signal a change in corporate strategy.
• Management: The filing confirms a significant passive investor, which may influence future investor relations efforts.
• Creditors: No direct impact is indicated by this filing.

Next Steps

• The reporting persons will continue to hold their shares in the ordinary course of business.
• Future amendments to this Schedule 13G will be filed as necessary to report changes in beneficial ownership.

Key Dates

Keywords

Avalo Therapeutics, Schedule 13G, Avoro Capital Advisors LLC, Behzad Aghazadeh, Beneficial Ownership, Common Stock, Investment, SEC Filing